dc.contributor.author | Olmedillas Cela, Eduardo | |
dc.contributor.author | Cano, Olga | |
dc.contributor.author | Martinez, Isidoro | |
dc.contributor.author | Luque, Daniel | |
dc.contributor.author | Terron-Orellana, Maria Carmen | |
dc.contributor.author | McLellan, Jason S | |
dc.contributor.author | Melero, Jose Antonio | |
dc.contributor.author | Mas-Lloret, Vicente | |
dc.date.accessioned | 2020-04-21T08:42:27Z | |
dc.date.available | 2020-04-21T08:42:27Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | EMBO Mol Med. 2018 Feb;10(2):175-187. | es_ES |
dc.identifier.issn | 1757-4676 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/9645 | |
dc.description.abstract | Human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV), two members of the Pneumoviridae family, account for the majority of severe lower respiratory tract infections worldwide in very young children. They are also a frequent cause of morbidity and mortality in the elderly and immunocompromised adults. High levels of neutralizing antibodies, mostly directed against the viral fusion (F) glycoprotein, correlate with protection against either hRSV or hMPV However, no cross-neutralization is observed in polyclonal antibody responses raised after virus infection or immunization with purified F proteins. Based on crystal structures of hRSV F and hMPV F, we designed chimeric F proteins in which certain residues of well-characterized antigenic sites were swapped between the two antigens. The antigenic changes were monitored by ELISA with virus-specific monoclonal antibodies. Inoculation of mice with these chimeras induced polyclonal cross-neutralizing antibody responses, and mice were protected against challenge with the virus used for grafting of the heterologous antigenic site. These results provide a proof of principle for chimeric fusion proteins as single immunogens that can induce cross-neutralizing antibody and protective responses against more than one human pneumovirus. | es_ES |
dc.description.sponsorship | We would like to thank the personnel of the Genomics and the Animal House facilities at Instituto de Salud Carlos III for their help in part of the work here presented. This work was supported in part by grants SAF2015‐67033‐R (JAM), PI15CIII/00024 (IM) from Instituto de Salud Carlos III, BFU 2013‐43149‐R (DL) from Plan Nacional I+D+I,c, and P20GM113132 (JSM) from the National Institute of General Medical Sciences of the National Institutes of Health. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Pneumoviridae | es_ES |
dc.subject | Neutralizing antibodies | es_ES |
dc.subject | Structure‐based design | es_ES |
dc.subject | Universal vaccines | es_ES |
dc.subject.mesh | Animals | es_ES |
dc.subject.mesh | Antibodies, Neutralizing | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Immunization | es_ES |
dc.subject.mesh | Mice | es_ES |
dc.subject.mesh | Models, Animal | es_ES |
dc.subject.mesh | Recombinant Fusion Proteins | es_ES |
dc.subject.mesh | Vaccines, Synthetic | es_ES |
dc.subject.mesh | Viral Fusion Proteins | es_ES |
dc.subject.mesh | Viral Vaccines | es_ES |
dc.subject.mesh | Metapneumovirus | es_ES |
dc.subject.mesh | Paramyxoviridae Infections | es_ES |
dc.subject.mesh | Respiratory Syncytial Virus Infections | es_ES |
dc.subject.mesh | Respiratory Syncytial Virus, Human | es_ES |
dc.title | Chimeric Pneumoviridae fusion proteins as immunogens to induce cross-neutralizing antibody responses | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 29217660 | es_ES |
dc.format.volume | 10 | es_ES |
dc.format.number | 2 | es_ES |
dc.format.page | 175-187 | es_ES |
dc.identifier.doi | 10.15252/emmm.201708078 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1757-4684 | es_ES |
dc.relation.publisherversion | https://doi.org/10.15252/emmm.201708078 | es_ES |
dc.identifier.journal | EMBO molecular medicine | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/SAF2015‐67033‐R | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/PI15CIII/00024 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/BFU 2013‐43149‐R | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/P20GM113132 | es_ES |
dc.rights.accessRights | open access | es_ES |